Ambagon Therapeutics
Biotechnology ResearchNorth Brabant, Netherlands11-50 Employees
Ambagon Therapeutics is a biotechnology company based in Eindhoven, North Brabant, Netherlands, focused on discovering and developing small-molecule cancer drugs that stabilize the direct interaction between oncogenic proteins and the 14-3-3 adaptor proteins. This approach seeks to create molecular glues that enable modulation of difficult protein targets with potential applications beyond oncology. The organization is relatively small and originated as a spin-off from Eindhoven University of Technology. A recent collaboration with Symeres will explore molecular glue research in colorectal cancer, reflecting active partnerships to expand this therapeutic modality. Beyond cancer, Ambagon's platform is framed to address broader clinical needs by stabilizing protein interactions in other disease contexts. The company has pursued research into LRRK2 activity in cells and preclinical models of Parkinson's disease, developing phosphorylation-stabilizing compounds to reduce disease-related effects in those models.
1-888-653-2347 
support@leadiq.com 
